PDF(Pubmed)
Abstract：
BACKGROUND: Gastric cancer is one of the most common cancers worldwide, with a 5-year survival rate of only 20%. The age of onset of gastric cancer is in line with the general rule of cancer. Most of them occur after middle age, mostly between 40 and 60 years old, with an average age of about 50 years old, and only 5% of patients are under 30 years old. The incidence of male is higher than that of female.
OBJECTIVE: To investigate the short-term efficacy and influencing factors of chemotherapy combined with irinotecan in patients with advanced gastric cancer.
METHODS: Eighty patients with advanced gastric cancer who were treated in our hospital from January 2019 to January 2022 were selected. The patients were divided into an observation group (n = 40) and control group (n = 40) by the envelope method. The control group was given preoperative routine chemotherapy. The observation group was treated with irinotecan in addition to the chemotherapy given to the control group. The short-term efficacy of treatment in the two groups, as well as tumor marker levels and quality of life before and after treatment were evaluated.
RESULTS: The short-term treatment effect in the observation group was better than that in the control group (P < 0.05), and the total effective rate was 57.50%. The age and proportion of tumor node metastasis (TNM) stage IV patients with ineffective chemotherapy in the observation group were (65.12 ± 5.71) years and 52.94%, respectively, which were notably higher than those of patients with effective chemotherapy (P < 0.05), while the Karnofsky Performance Scale score was (67.70 ± 3.83) points, which was apparently lower than that of patients with effective chemotherapy (P < 0.05). After 3 mo of treatment, the SF-36 scale scores of physiological function, energy, emotional function, and mental health in the observation group were 65.12 ± 8.14, 54.76 ± 6.70, 47.58 ± 7.22, and 66.16 ± 8.11 points, respectively, which were considerably higher than those in the control group (P < 0.05). The incidence rates of grade III-IV diarrhea and grade III-IV thrombocytopenia in the observation group were 32.50% and 25.00%, respectively, which were markedly higher than those in the control group (P < 0.05).
CONCLUSIONS: Chemotherapy combined with irinotecan in patients with advanced gastric cancer has a good short-term efficacy and can significantly reduce serum tumor markers and improve the quality of life of patients. The efficacy may be affected by the age and TNM stage of the patients, and its long-term efficacy needs further study.
OBJECTIVE: To investigate the short-term efficacy and influencing factors of chemotherapy combined with irinotecan in patients with advanced gastric cancer.
METHODS: Eighty patients with advanced gastric cancer who were treated in our hospital from January 2019 to January 2022 were selected. The patients were divided into an observation group (n = 40) and control group (n = 40) by the envelope method. The control group was given preoperative routine chemotherapy. The observation group was treated with irinotecan in addition to the chemotherapy given to the control group. The short-term efficacy of treatment in the two groups, as well as tumor marker levels and quality of life before and after treatment were evaluated.
RESULTS: The short-term treatment effect in the observation group was better than that in the control group (P < 0.05), and the total effective rate was 57.50%. The age and proportion of tumor node metastasis (TNM) stage IV patients with ineffective chemotherapy in the observation group were (65.12 ± 5.71) years and 52.94%, respectively, which were notably higher than those of patients with effective chemotherapy (P < 0.05), while the Karnofsky Performance Scale score was (67.70 ± 3.83) points, which was apparently lower than that of patients with effective chemotherapy (P < 0.05). After 3 mo of treatment, the SF-36 scale scores of physiological function, energy, emotional function, and mental health in the observation group were 65.12 ± 8.14, 54.76 ± 6.70, 47.58 ± 7.22, and 66.16 ± 8.11 points, respectively, which were considerably higher than those in the control group (P < 0.05). The incidence rates of grade III-IV diarrhea and grade III-IV thrombocytopenia in the observation group were 32.50% and 25.00%, respectively, which were markedly higher than those in the control group (P < 0.05).
CONCLUSIONS: Chemotherapy combined with irinotecan in patients with advanced gastric cancer has a good short-term efficacy and can significantly reduce serum tumor markers and improve the quality of life of patients. The efficacy may be affected by the age and TNM stage of the patients, and its long-term efficacy needs further study.
摘要：
背景：胃癌是全球最常见的癌症之一，5年生存率仅为20%。胃癌的发病年龄符合癌症的一般规律。大多数发生在中年以后，大多在40到60岁之间，平均年龄约50岁，只有5%的患者年龄在30岁以下。男性发病率高于女性。
目的：探讨化疗联合伊立替康治疗晚期胃癌的近期疗效及影响因素。
方法：选取我院2019年1月至2022年1月收治的晚期胃癌患者80例。采用信封法将患者分为观察组(n=40)和对照组(n=40)。对照组给予术前常规化疗。观察组在对照组化疗的基础上给予伊立替康治疗。两组治疗的近期疗效,以及治疗前后的肿瘤标志物水平和生活质量进行评价。
结果：观察组近期治疗效果优于对照组（P<0.05）。总有效率为57.50%。观察组化疗无效的肿瘤淋巴结转移(TNM)IV期患者的年龄和比例分别为(65.12±5.71)岁和52.94%,分别,显著高于化疗有效患者(P<0.05),Karnofsky绩效量表得分为（67.70±3.83）分，明显低于化疗有效患者(P<0.05)。经过3个月的治疗，SF-36量表的生理功能评分，能源,情感功能,观察组心理健康分别为65.12±8.14、54.76±6.70、47.58±7.22和66.16±8.11分,分别,显著高于对照组(P<0.05)。观察组III-IV级腹泻和III-IV级血小板减少发生率分别为32.50%和25.00%,分别,显著高于对照组(P<0.05)。
结论：化疗联合伊立替康治疗晚期胃癌近期疗效较好，可显著降低患者血清肿瘤标志物水平，提高患者生活质量。疗效可能受患者年龄和TNM分期的影响,其长期疗效有待进一步研究。
目的：探讨化疗联合伊立替康治疗晚期胃癌的近期疗效及影响因素。
方法：选取我院2019年1月至2022年1月收治的晚期胃癌患者80例。采用信封法将患者分为观察组(n=40)和对照组(n=40)。对照组给予术前常规化疗。观察组在对照组化疗的基础上给予伊立替康治疗。两组治疗的近期疗效,以及治疗前后的肿瘤标志物水平和生活质量进行评价。
结果：观察组近期治疗效果优于对照组（P<0.05）。总有效率为57.50%。观察组化疗无效的肿瘤淋巴结转移(TNM)IV期患者的年龄和比例分别为(65.12±5.71)岁和52.94%,分别,显著高于化疗有效患者(P<0.05),Karnofsky绩效量表得分为（67.70±3.83）分，明显低于化疗有效患者(P<0.05)。经过3个月的治疗，SF-36量表的生理功能评分，能源,情感功能,观察组心理健康分别为65.12±8.14、54.76±6.70、47.58±7.22和66.16±8.11分,分别,显著高于对照组(P<0.05)。观察组III-IV级腹泻和III-IV级血小板减少发生率分别为32.50%和25.00%,分别,显著高于对照组(P<0.05)。
结论：化疗联合伊立替康治疗晚期胃癌近期疗效较好，可显著降低患者血清肿瘤标志物水平，提高患者生活质量。疗效可能受患者年龄和TNM分期的影响,其长期疗效有待进一步研究。
